Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rolf Hjortkjaer"'
Publikováno v:
British Journal of Clinical Pharmacology. 70:580-587
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? • Systemic anaphylactic reactions have been described as rare but serious adverse effects of GnRH antagonists. • The chemical development of degarelix has devoted much attention to the elimination of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08cc60bbb97db8c51b3443a4b91ebfc6
https://doi.org/10.1111/j.1365-2125.2010.03730.x
https://doi.org/10.1111/j.1365-2125.2010.03730.x
Publikováno v:
British journal of clinical pharmacology. 70(4)
Early studies on gonadotrophin-releasing hormone (GnRH) antagonists pointed out histamine-mediated anaphylactic reactions as a potential adverse effect of these drug candidates. In this study we have compared the histamine-releasing potential of four
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72c5490492cfeb3b2dd1068cb5903b24
https://pubmed.ncbi.nlm.nih.gov/20840449
https://pubmed.ncbi.nlm.nih.gov/20840449
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 20(3)
Degarelix (FE200486) is a new GnRH-receptor antagonist intended for the treatment of prostate cancer. The objective of the present analysis was to evaluate the pharmacokinetics of degarelix after subcutaneous (s.c.) and intra-muscular (i.m.) administ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8598de103fff44c254147b544f877a78
https://pubmed.ncbi.nlm.nih.gov/14592699
https://pubmed.ncbi.nlm.nih.gov/14592699